A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01241591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1101

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CP 690,550 5 mg
DRUG: CP 690,550 10 mg
BIOLOGICAL: Etanercept 50 mg
OTHER: Placebo

Sponsor

Pfizer